Which has preferable valuation & earnings, DMAC or AVBP?

DiaMedica Therapeutics is trading at a lower price-to-earnings ratio than ArriVent BioPharma, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio DiaMedica Therapeutics N/A N/A -$32.77M -$0.72 N/A ArriVent BioPharma N/A N/A -$166.31M -$3.47 N/A

Is DMAC or AVBP more profitable?

ArriVent BioPharma's return on equity of -50.26% beat DiaMedica Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets DiaMedica Therapeutics N/A -77.76% -69.43% ArriVent BioPharma N/A -50.26% -46.66%

Does the media prefer DMAC or AVBP?

In the previous week, DiaMedica Therapeutics had 8 more articles in the media than ArriVent BioPharma. MarketBeat recorded 20 mentions for DiaMedica Therapeutics and 12 mentions for ArriVent BioPharma. DiaMedica Therapeutics' average media sentiment score of 0.75 beat ArriVent BioPharma's score of 0.24 indicating that DiaMedica Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment DiaMedica Therapeutics 4 Very Positive mention(s) 2 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive ArriVent BioPharma 2 Very Positive mention(s) 4 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral

Which has preferable valuation & earnings, DMAC or ORIC?

Oric Pharmaceuticals is trading at a lower price-to-earnings ratio than DiaMedica Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio DiaMedica Therapeutics N/A N/A -$32.77M -$0.72 N/A Oric Pharmaceuticals N/A N/A -$129.47M -$1.35 N/A

Is DMAC or ORIC more profitable?

Oric Pharmaceuticals' return on equity of -35.35% beat DiaMedica Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets DiaMedica Therapeutics N/A -77.76% -69.43% Oric Pharmaceuticals N/A -35.35% -33.39%

Does the media refer more to DMAC or ORIC?

In the previous week, DiaMedica Therapeutics had 3 more articles in the media than Oric Pharmaceuticals. MarketBeat recorded 20 mentions for DiaMedica Therapeutics and 17 mentions for Oric Pharmaceuticals. DiaMedica Therapeutics' average media sentiment score of 0.75 beat Oric Pharmaceuticals' score of 0.59 indicating that DiaMedica Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment DiaMedica Therapeutics 4 Very Positive mention(s) 2 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Oric Pharmaceuticals 3 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to DMAC or ABSI?

In the previous week, DiaMedica Therapeutics had 4 more articles in the media than Absci. MarketBeat recorded 20 mentions for DiaMedica Therapeutics and 16 mentions for Absci. DiaMedica Therapeutics' average media sentiment score of 0.75 beat Absci's score of -0.11 indicating that DiaMedica Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment DiaMedica Therapeutics 4 Very Positive mention(s) 2 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Absci 0 Very Positive mention(s) 4 Positive mention(s) 6 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Neutral

Which has stronger earnings & valuation, DMAC or MLTX?

DiaMedica Therapeutics is trading at a lower price-to-earnings ratio than MoonLake Immunotherapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio DiaMedica Therapeutics N/A N/A -$32.77M -$0.72 N/A MoonLake Immunotherapeutics N/A N/A -$227.32M -$3.84 N/A

Is DMAC or MLTX more profitable?

DiaMedica Therapeutics' return on equity of -77.76% beat MoonLake Immunotherapeutics' return on equity. Company Net Margins Return on Equity Return on Assets DiaMedica Therapeutics N/A -77.76% -69.43% MoonLake Immunotherapeutics N/A -82.53% -58.17%

Does the media favor DMAC or MLTX?

In the previous week, DiaMedica Therapeutics and DiaMedica Therapeutics both had 20 articles in the media. MoonLake Immunotherapeutics' average media sentiment score of 0.91 beat DiaMedica Therapeutics' score of 0.75 indicating that MoonLake Immunotherapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment DiaMedica Therapeutics 4 Very Positive mention(s) 2 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive MoonLake Immunotherapeutics 8 Very Positive mention(s) 3 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer GLUE or DMAC?

In the previous week, DiaMedica Therapeutics had 14 more articles in the media than Monte Rosa Therapeutics. MarketBeat recorded 20 mentions for DiaMedica Therapeutics and 6 mentions for Monte Rosa Therapeutics. DiaMedica Therapeutics' average media sentiment score of 0.75 beat Monte Rosa Therapeutics' score of 0.06 indicating that DiaMedica Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Monte Rosa Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 2 Negative mention(s) 1 Very Negative mention(s) Neutral DiaMedica Therapeutics 4 Very Positive mention(s) 2 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

DiaMedica Therapeutics (DMAC) Competitors

$6.68 -0.07 (-1.04%)

Closing price 04:00 PM Eastern

Extended Trading

$6.53 -0.15 (-2.31%)

As of 07:34 PM Eastern

Compare

DMAC vs. AVBP, ORIC, ABSI, MLTX, and GLUE

Should you buy DiaMedica Therapeutics stock or one of its competitors? DiaMedica Therapeutics's main competitors and comparable companies include ArriVent BioPharma (AVBP), Oric Pharmaceuticals (ORIC), Absci (ABSI), MoonLake Immunotherapeutics (MLTX), and Monte Rosa Therapeutics (GLUE). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does DiaMedica Therapeutics compare to ArriVent BioPharma?

DiaMedica Therapeutics (NASDAQ:DMAC) and ArriVent BioPharma (NASDAQ:AVBP) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, valuation, dividends, institutional ownership, risk, earnings, analyst recommendations and media sentiment.

DiaMedica Therapeutics has a beta of 1.01, meaning that its share price is 1% more volatile than the broader market. Comparatively, ArriVent BioPharma has a beta of 1.36, meaning that its share price is 36% more volatile than the broader market.

DiaMedica Therapeutics presently has a consensus price target of $12.00, indicating a potential upside of 79.64%. ArriVent BioPharma has a consensus price target of $44.43, indicating a potential upside of 50.55%. Given DiaMedica Therapeutics' higher probable upside, equities analysts clearly believe DiaMedica Therapeutics is more favorable than ArriVent BioPharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
DiaMedica Therapeutics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60
ArriVent BioPharma	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.70

ArriVent BioPharma's return on equity of -50.26% beat DiaMedica Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
DiaMedica Therapeutics	N/A	-77.76%	-69.43%
ArriVent BioPharma	N/A	-50.26%	-46.66%

10.1% of DiaMedica Therapeutics shares are held by institutional investors. Comparatively, 9.5% of ArriVent BioPharma shares are held by institutional investors. 5.0% of DiaMedica Therapeutics shares are held by insiders. Comparatively, 8.6% of ArriVent BioPharma shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

DiaMedica Therapeutics is trading at a lower price-to-earnings ratio than ArriVent BioPharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
DiaMedica Therapeutics	N/A	N/A	-$32.77M	-$0.72	N/A
ArriVent BioPharma	N/A	N/A	-$166.31M	-$3.47	N/A

In the previous week, DiaMedica Therapeutics had 8 more articles in the media than ArriVent BioPharma. MarketBeat recorded 20 mentions for DiaMedica Therapeutics and 12 mentions for ArriVent BioPharma. DiaMedica Therapeutics' average media sentiment score of 0.75 beat ArriVent BioPharma's score of 0.24 indicating that DiaMedica Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
DiaMedica Therapeutics	4 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
ArriVent BioPharma	2 Very Positive mention(s)	4 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

Summary

ArriVent BioPharma beats DiaMedica Therapeutics on 7 of the 13 factors compared between the two stocks.

How does DiaMedica Therapeutics compare to Oric Pharmaceuticals?

DiaMedica Therapeutics (NASDAQ:DMAC) and Oric Pharmaceuticals (NASDAQ:ORIC) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, media sentiment, dividends, analyst recommendations, earnings, risk, profitability and valuation.

DiaMedica Therapeutics has a beta of 1.01, indicating that its share price is 1% more volatile than the broader market. Comparatively, Oric Pharmaceuticals has a beta of 1.02, indicating that its share price is 2% more volatile than the broader market.

Oric Pharmaceuticals' return on equity of -35.35% beat DiaMedica Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
DiaMedica Therapeutics	N/A	-77.76%	-69.43%
Oric Pharmaceuticals	N/A	-35.35%	-33.39%

10.1% of DiaMedica Therapeutics shares are owned by institutional investors. Comparatively, 95.1% of Oric Pharmaceuticals shares are owned by institutional investors. 5.0% of DiaMedica Therapeutics shares are owned by company insiders. Comparatively, 5.7% of Oric Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

In the previous week, DiaMedica Therapeutics had 3 more articles in the media than Oric Pharmaceuticals. MarketBeat recorded 20 mentions for DiaMedica Therapeutics and 17 mentions for Oric Pharmaceuticals. DiaMedica Therapeutics' average media sentiment score of 0.75 beat Oric Pharmaceuticals' score of 0.59 indicating that DiaMedica Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
DiaMedica Therapeutics	4 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Oric Pharmaceuticals	3 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Oric Pharmaceuticals is trading at a lower price-to-earnings ratio than DiaMedica Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
DiaMedica Therapeutics	N/A	N/A	-$32.77M	-$0.72	N/A
Oric Pharmaceuticals	N/A	N/A	-$129.47M	-$1.35	N/A

DiaMedica Therapeutics presently has a consensus price target of $12.00, indicating a potential upside of 79.64%. Oric Pharmaceuticals has a consensus price target of $19.45, indicating a potential upside of 40.26%. Given DiaMedica Therapeutics' higher probable upside, equities research analysts clearly believe DiaMedica Therapeutics is more favorable than Oric Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
DiaMedica Therapeutics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60
Oric Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.80

Summary

Oric Pharmaceuticals beats DiaMedica Therapeutics on 7 of the 13 factors compared between the two stocks.

How does DiaMedica Therapeutics compare to Absci?

DiaMedica Therapeutics (NASDAQ:DMAC) and Absci (NASDAQ:ABSI) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, analyst recommendations, profitability, risk, earnings, media sentiment, valuation and institutional ownership.

DiaMedica Therapeutics currently has a consensus price target of $12.00, suggesting a potential upside of 79.64%. Absci has a consensus price target of $13.43, suggesting a potential upside of 46.28%. Given DiaMedica Therapeutics' higher probable upside, equities analysts clearly believe DiaMedica Therapeutics is more favorable than Absci.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
DiaMedica Therapeutics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60
Absci	1 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.78

10.1% of DiaMedica Therapeutics shares are held by institutional investors. Comparatively, 52.1% of Absci shares are held by institutional investors. 5.0% of DiaMedica Therapeutics shares are held by company insiders. Comparatively, 10.5% of Absci shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

DiaMedica Therapeutics has a beta of 1.01, indicating that its share price is 1% more volatile than the broader market. Comparatively, Absci has a beta of 2.35, indicating that its share price is 135% more volatile than the broader market.

DiaMedica Therapeutics has a net margin of 0.00% compared to Absci's net margin of -7,756.38%. Absci's return on equity of -61.71% beat DiaMedica Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
DiaMedica Therapeutics	N/A	-77.76%	-69.43%
Absci	-7,756.38%	-61.71%	-54.52%

DiaMedica Therapeutics has higher earnings, but lower revenue than Absci. Absci is trading at a lower price-to-earnings ratio than DiaMedica Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
DiaMedica Therapeutics	N/A	N/A	-$32.77M	-$0.72	N/A
Absci	$2.80M	562.64	-$115.18M	-$0.83	N/A

In the previous week, DiaMedica Therapeutics had 4 more articles in the media than Absci. MarketBeat recorded 20 mentions for DiaMedica Therapeutics and 16 mentions for Absci. DiaMedica Therapeutics' average media sentiment score of 0.75 beat Absci's score of -0.11 indicating that DiaMedica Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
DiaMedica Therapeutics	4 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Absci	0 Very Positive mention(s)	4 Positive mention(s)	6 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Neutral

Summary

Absci beats DiaMedica Therapeutics on 8 of the 15 factors compared between the two stocks.

How does DiaMedica Therapeutics compare to MoonLake Immunotherapeutics?

DiaMedica Therapeutics (NASDAQ:DMAC) and MoonLake Immunotherapeutics (NASDAQ:MLTX) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, dividends, media sentiment, risk, earnings, profitability, analyst recommendations and valuation.

DiaMedica Therapeutics presently has a consensus price target of $12.00, suggesting a potential upside of 79.64%. MoonLake Immunotherapeutics has a consensus price target of $24.57, suggesting a potential upside of 49.19%. Given DiaMedica Therapeutics' stronger consensus rating and higher probable upside, equities analysts clearly believe DiaMedica Therapeutics is more favorable than MoonLake Immunotherapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
DiaMedica Therapeutics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60
MoonLake Immunotherapeutics	3 Sell rating(s)	4 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.41

DiaMedica Therapeutics has a beta of 1.01, meaning that its share price is 1% more volatile than the broader market. Comparatively, MoonLake Immunotherapeutics has a beta of 1.06, meaning that its share price is 6% more volatile than the broader market.

DiaMedica Therapeutics is trading at a lower price-to-earnings ratio than MoonLake Immunotherapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
DiaMedica Therapeutics	N/A	N/A	-$32.77M	-$0.72	N/A
MoonLake Immunotherapeutics	N/A	N/A	-$227.32M	-$3.84	N/A

DiaMedica Therapeutics' return on equity of -77.76% beat MoonLake Immunotherapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
DiaMedica Therapeutics	N/A	-77.76%	-69.43%
MoonLake Immunotherapeutics	N/A	-82.53%	-58.17%

10.1% of DiaMedica Therapeutics shares are owned by institutional investors. Comparatively, 93.9% of MoonLake Immunotherapeutics shares are owned by institutional investors. 5.0% of DiaMedica Therapeutics shares are owned by company insiders. Comparatively, 10.4% of MoonLake Immunotherapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

In the previous week, DiaMedica Therapeutics and DiaMedica Therapeutics both had 20 articles in the media. MoonLake Immunotherapeutics' average media sentiment score of 0.91 beat DiaMedica Therapeutics' score of 0.75 indicating that MoonLake Immunotherapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
DiaMedica Therapeutics	4 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
MoonLake Immunotherapeutics	8 Very Positive mention(s)	3 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

MoonLake Immunotherapeutics beats DiaMedica Therapeutics on 7 of the 12 factors compared between the two stocks.

How does DiaMedica Therapeutics compare to Monte Rosa Therapeutics?

Monte Rosa Therapeutics (NASDAQ:GLUE) and DiaMedica Therapeutics (NASDAQ:DMAC) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, earnings, media sentiment, valuation, institutional ownership, profitability, risk and analyst recommendations.

DiaMedica Therapeutics has a net margin of 0.00% compared to Monte Rosa Therapeutics' net margin of -560.85%. Monte Rosa Therapeutics' return on equity of -43.31% beat DiaMedica Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Monte Rosa Therapeutics	-560.85%	-43.31%	-27.59%
DiaMedica Therapeutics	N/A	-77.76%	-69.43%

In the previous week, DiaMedica Therapeutics had 14 more articles in the media than Monte Rosa Therapeutics. MarketBeat recorded 20 mentions for DiaMedica Therapeutics and 6 mentions for Monte Rosa Therapeutics. DiaMedica Therapeutics' average media sentiment score of 0.75 beat Monte Rosa Therapeutics' score of 0.06 indicating that DiaMedica Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Monte Rosa Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	2 Negative mention(s)	1 Very Negative mention(s)	Neutral
DiaMedica Therapeutics	4 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

DiaMedica Therapeutics has lower revenue, but higher earnings than Monte Rosa Therapeutics. DiaMedica Therapeutics is trading at a lower price-to-earnings ratio than Monte Rosa Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Monte Rosa Therapeutics	$123.67M	10.69	-$38.63M	-$1.76	N/A
DiaMedica Therapeutics	N/A	N/A	-$32.77M	-$0.72	N/A

Monte Rosa Therapeutics currently has a consensus price target of $28.50, indicating a potential upside of 83.87%. DiaMedica Therapeutics has a consensus price target of $12.00, indicating a potential upside of 79.64%. Given Monte Rosa Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Monte Rosa Therapeutics is more favorable than DiaMedica Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Monte Rosa Therapeutics	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.67
DiaMedica Therapeutics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60

Monte Rosa Therapeutics has a beta of 1.59, suggesting that its share price is 59% more volatile than the broader market. Comparatively, DiaMedica Therapeutics has a beta of 1.01, suggesting that its share price is 1% more volatile than the broader market.

80.0% of Monte Rosa Therapeutics shares are held by institutional investors. Comparatively, 10.1% of DiaMedica Therapeutics shares are held by institutional investors. 6.4% of Monte Rosa Therapeutics shares are held by insiders. Comparatively, 5.0% of DiaMedica Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Summary

Monte Rosa Therapeutics beats DiaMedica Therapeutics on 10 of the 15 factors compared between the two stocks.

Get DiaMedica Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding DMAC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

DMAC vs. The Competition

Export

Metric	DiaMedica Therapeutics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$364M	$3.74B	$7.06B	$13.10B
Dividend Yield	N/A	3.69%	2.57%	10.45%
P/E Ratio	-9.28	10.67	269.06	25.28
Price / Sales	N/A	1,294.08	602.43	91.76
Price / Cash	N/A	102.88	70.48	50.90
Price / Book	9.41	16.78	12.91	6.24
Net Income	-$32.77M	-$13.32M	$3.45B	$347.60M
7 Day Performance	-1.04%	1.74%	1.12%	1.07%
1 Month Performance	-10.09%	1.60%	1.79%	1.03%
1 Year Performance	11.15%	56.43%	67.69%	20.77%

DiaMedica Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
DMAC DiaMedica Therapeutics	1.755 of 5 stars	$6.68 -1.0%	$12.00 +79.6%	+12.5%	$364M	N/A	N/A	20	Trending News Earnings Report Analyst Forecast Analyst Revision
AVBP ArriVent BioPharma	2.3669 of 5 stars	$30.84 -0.5%	$44.83 +45.4%	+66.5%	$1.44B	N/A	N/A	40	News Coverage Earnings Report Analyst Forecast
ORIC Oric Pharmaceuticals	2.3646 of 5 stars	$13.50 +4.4%	$19.27 +42.8%	+39.6%	$1.40B	N/A	N/A	80	Analyst Revision
ABSI Absci	2.1424 of 5 stars	$8.93 +7.6%	$13.43 +50.4%	+203.2%	$1.39B	$2.80M	N/A	210	News Coverage Earnings Report Analyst Forecast
MLTX MoonLake Immunotherapeutics	3.5119 of 5 stars	$18.26 +1.3%	$24.21 +32.6%	-70.4%	$1.34B	N/A	N/A	2	Earnings Report Analyst Forecast Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:DMAC) was last updated on 8/14/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

DiaMedica Therapeutics (DMAC) Competitors

DMAC vs. AVBP, ORIC, ABSI, MLTX, and GLUE

How does DiaMedica Therapeutics compare to ArriVent BioPharma?

Summary

How does DiaMedica Therapeutics compare to Oric Pharmaceuticals?

Summary

How does DiaMedica Therapeutics compare to Absci?

Summary

How does DiaMedica Therapeutics compare to MoonLake Immunotherapeutics?

Summary

How does DiaMedica Therapeutics compare to Monte Rosa Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

DMAC vs. The Competition

DiaMedica Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

DiaMedica Therapeutics (DMAC) Competitors

DMAC vs. AVBP, ORIC, ABSI, MLTX, and GLUE

How does DiaMedica Therapeutics compare to ArriVent BioPharma?

Which has more volatility & risk, DMAC or AVBP?

Do analysts recommend DMAC or AVBP?

Is DMAC or AVBP more profitable?

Do institutionals and insiders believe in DMAC or AVBP?

Which has preferable valuation & earnings, DMAC or AVBP?

Does the media prefer DMAC or AVBP?

Summary

How does DiaMedica Therapeutics compare to Oric Pharmaceuticals?

Which has more volatility and risk, DMAC or ORIC?

Is DMAC or ORIC more profitable?

Do insiders & institutionals have more ownership in DMAC or ORIC?

Does the media refer more to DMAC or ORIC?

Which has preferable valuation & earnings, DMAC or ORIC?

Do analysts prefer DMAC or ORIC?

Summary

How does DiaMedica Therapeutics compare to Absci?

Do analysts prefer DMAC or ABSI?

Do insiders and institutionals hold more shares of DMAC or ABSI?

Which has more volatility and risk, DMAC or ABSI?

Is DMAC or ABSI more profitable?

Which has preferable valuation and earnings, DMAC or ABSI?

Does the media refer more to DMAC or ABSI?

Summary

How does DiaMedica Therapeutics compare to MoonLake Immunotherapeutics?

Do analysts rate DMAC or MLTX?

Which has more volatility and risk, DMAC or MLTX?

Which has stronger earnings & valuation, DMAC or MLTX?

Is DMAC or MLTX more profitable?

Do institutionals and insiders hold more shares of DMAC or MLTX?

Does the media favor DMAC or MLTX?

Summary

How does DiaMedica Therapeutics compare to Monte Rosa Therapeutics?

Is GLUE or DMAC more profitable?

Does the media prefer GLUE or DMAC?

Which has stronger valuation and earnings, GLUE or DMAC?

Do analysts rate GLUE or DMAC?

Which has more volatility & risk, GLUE or DMAC?

Do insiders & institutionals hold more shares of GLUE or DMAC?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

DMAC vs. The Competition

DiaMedica Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools